You just read:

BioMarin Submits Marketing Authorization Application to European Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A

News provided by

BioMarin Pharmaceutical Inc.

Nov 21, 2019, 16:04 ET